Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver Cirrhosis
BACKGROUNDTreatment of portal vein thrombosis (PVT) in patients with liver cirrhosis is not well established. AIMWe intended to assess the safety and efficacy of low molecular weight heparin (LMWH) to treat PVT in cirrhotic patients. STUDYAll 39 patients diagnosed with non-neoplastic PVT and cirrhos...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical gastroenterology 2010-07, Vol.44 (6), p.448-451 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 451 |
|---|---|
| container_issue | 6 |
| container_start_page | 448 |
| container_title | Journal of clinical gastroenterology |
| container_volume | 44 |
| creator | Amitrano, Lucio Guardascione, Maria Anna Menchise, Antonella Martino, Rossana Scaglione, Mariano Giovine, Sabrina Romano, Luigia Balzano, Antonio |
| description | BACKGROUNDTreatment of portal vein thrombosis (PVT) in patients with liver cirrhosis is not well established.
AIMWe intended to assess the safety and efficacy of low molecular weight heparin (LMWH) to treat PVT in cirrhotic patients.
STUDYAll 39 patients diagnosed with non-neoplastic PVT and cirrhosis from June 2005 to December 2006 were evaluated for anticoagulation therapy (AT). PVT was occludent in 15.4%, partial in 64.1%, and portal cavernoma presented in 20.5%. Twenty-eight patients received 200 U/kg/d of enoxaparin for at least 6 months. In 39.3% of patients PVT was an occasional finding, in 10.7% presented with acute abdominal pain, in 50% with bleeding from gastroesophageal varices. In this last group LMWH was started after endoscopic eradication of varices by band ligation.
RESULTSComplete recanalization of portal vein occurred in 33.3%, partial recanalization in 50% and no response in 16.7% of patients. Further 12 patients who continued AT obtained complete recanalization at a median time of 11 months (range 7 to 17 mo). Overall, a complete response was obtained in 75% of patients. No significant side effects, particularly bleeding complications, were observed during the treatment.
CONCLUSIONSLMWH demonstrated safe and effective in the treatment of PVT in patients with liver cirrhosis. |
| doi_str_mv | 10.1097/MCG.0b013e3181b3ab44 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733356556</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733356556</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3817-5a3cff8ac1b7739b87e6e373d7f95442487e1e2fadaf291b54d2c8466a88d6e83</originalsourceid><addsrcrecordid>eNpdkd1u1DAQhS0EokvhDRDyDeIqxY6dOLmsVv1B2opKFHoZTZxxY_DGi-2w2nfgofHSiErMzWjs75yR5hDylrMzzlr18WZ9dcZ6xgUK3vBeQC_lM7LilWiLkgn-nKwYb8uCqZadkFcxfmeMKyH4S3LCWyUY5-WK_P4CBtOBwjTQC2OsBn2g3tDzKVnt4WF2kKyf6N2IAXYHem_TSDd-T2-8Q51_A71H-zAmeo07CHaixgd660MCR7-hPSqD3_Y-2kjzdJvtcEpxMbK_MNC1DWE8Aq_JCwMu4puln5Kvlxd36-ti8_nq0_p8U2jRcFVUILQxDWjeKyXavlFYo1BiUKatpCxlfuBYGhjAlC3vKzmUupF1DU0z1NiIU_Lh0XcX_M8ZY-q2Nmp0Dib0c-zylURVV1WdSflI6uBjDGi6XbBbCIeOs-4YQ5dj6P6PIcveLQvmfovDk2i5ewbeLwBEDc4EmLSN_7iybCWTtXzav_cuYYg_3LzH0I0ILo0dyyUbUee8OWMqTwX7G_If1CSirQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733356556</pqid></control><display><type>article</type><title>Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver Cirrhosis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Amitrano, Lucio ; Guardascione, Maria Anna ; Menchise, Antonella ; Martino, Rossana ; Scaglione, Mariano ; Giovine, Sabrina ; Romano, Luigia ; Balzano, Antonio</creator><creatorcontrib>Amitrano, Lucio ; Guardascione, Maria Anna ; Menchise, Antonella ; Martino, Rossana ; Scaglione, Mariano ; Giovine, Sabrina ; Romano, Luigia ; Balzano, Antonio</creatorcontrib><description>BACKGROUNDTreatment of portal vein thrombosis (PVT) in patients with liver cirrhosis is not well established.
AIMWe intended to assess the safety and efficacy of low molecular weight heparin (LMWH) to treat PVT in cirrhotic patients.
STUDYAll 39 patients diagnosed with non-neoplastic PVT and cirrhosis from June 2005 to December 2006 were evaluated for anticoagulation therapy (AT). PVT was occludent in 15.4%, partial in 64.1%, and portal cavernoma presented in 20.5%. Twenty-eight patients received 200 U/kg/d of enoxaparin for at least 6 months. In 39.3% of patients PVT was an occasional finding, in 10.7% presented with acute abdominal pain, in 50% with bleeding from gastroesophageal varices. In this last group LMWH was started after endoscopic eradication of varices by band ligation.
RESULTSComplete recanalization of portal vein occurred in 33.3%, partial recanalization in 50% and no response in 16.7% of patients. Further 12 patients who continued AT obtained complete recanalization at a median time of 11 months (range 7 to 17 mo). Overall, a complete response was obtained in 75% of patients. No significant side effects, particularly bleeding complications, were observed during the treatment.
CONCLUSIONSLMWH demonstrated safe and effective in the treatment of PVT in patients with liver cirrhosis.</description><identifier>ISSN: 0192-0790</identifier><identifier>EISSN: 1539-2031</identifier><identifier>DOI: 10.1097/MCG.0b013e3181b3ab44</identifier><identifier>PMID: 19730112</identifier><identifier>CODEN: JCGADC</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Aged ; Anticoagulants - administration & dosage ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood. Blood coagulation. Reticuloendothelial system ; Cardiology. Vascular system ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Heparin, Low-Molecular-Weight - administration & dosage ; Heparin, Low-Molecular-Weight - adverse effects ; Heparin, Low-Molecular-Weight - therapeutic use ; Humans ; Liver Cirrhosis - complications ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Pharmacology. Drug treatments ; Portal Vein ; Treatment Outcome ; Venous Thrombosis - drug therapy ; Venous Thrombosis - etiology</subject><ispartof>Journal of clinical gastroenterology, 2010-07, Vol.44 (6), p.448-451</ispartof><rights>2010 Lippincott Williams & Wilkins, Inc.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3817-5a3cff8ac1b7739b87e6e373d7f95442487e1e2fadaf291b54d2c8466a88d6e83</citedby><cites>FETCH-LOGICAL-c3817-5a3cff8ac1b7739b87e6e373d7f95442487e1e2fadaf291b54d2c8466a88d6e83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22940464$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19730112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Amitrano, Lucio</creatorcontrib><creatorcontrib>Guardascione, Maria Anna</creatorcontrib><creatorcontrib>Menchise, Antonella</creatorcontrib><creatorcontrib>Martino, Rossana</creatorcontrib><creatorcontrib>Scaglione, Mariano</creatorcontrib><creatorcontrib>Giovine, Sabrina</creatorcontrib><creatorcontrib>Romano, Luigia</creatorcontrib><creatorcontrib>Balzano, Antonio</creatorcontrib><title>Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver Cirrhosis</title><title>Journal of clinical gastroenterology</title><addtitle>J Clin Gastroenterol</addtitle><description>BACKGROUNDTreatment of portal vein thrombosis (PVT) in patients with liver cirrhosis is not well established.
AIMWe intended to assess the safety and efficacy of low molecular weight heparin (LMWH) to treat PVT in cirrhotic patients.
STUDYAll 39 patients diagnosed with non-neoplastic PVT and cirrhosis from June 2005 to December 2006 were evaluated for anticoagulation therapy (AT). PVT was occludent in 15.4%, partial in 64.1%, and portal cavernoma presented in 20.5%. Twenty-eight patients received 200 U/kg/d of enoxaparin for at least 6 months. In 39.3% of patients PVT was an occasional finding, in 10.7% presented with acute abdominal pain, in 50% with bleeding from gastroesophageal varices. In this last group LMWH was started after endoscopic eradication of varices by band ligation.
RESULTSComplete recanalization of portal vein occurred in 33.3%, partial recanalization in 50% and no response in 16.7% of patients. Further 12 patients who continued AT obtained complete recanalization at a median time of 11 months (range 7 to 17 mo). Overall, a complete response was obtained in 75% of patients. No significant side effects, particularly bleeding complications, were observed during the treatment.
CONCLUSIONSLMWH demonstrated safe and effective in the treatment of PVT in patients with liver cirrhosis.</description><subject>Aged</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Cardiology. Vascular system</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Heparin, Low-Molecular-Weight - administration & dosage</subject><subject>Heparin, Low-Molecular-Weight - adverse effects</subject><subject>Heparin, Low-Molecular-Weight - therapeutic use</subject><subject>Humans</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Other diseases. Semiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Portal Vein</subject><subject>Treatment Outcome</subject><subject>Venous Thrombosis - drug therapy</subject><subject>Venous Thrombosis - etiology</subject><issn>0192-0790</issn><issn>1539-2031</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkd1u1DAQhS0EokvhDRDyDeIqxY6dOLmsVv1B2opKFHoZTZxxY_DGi-2w2nfgofHSiErMzWjs75yR5hDylrMzzlr18WZ9dcZ6xgUK3vBeQC_lM7LilWiLkgn-nKwYb8uCqZadkFcxfmeMKyH4S3LCWyUY5-WK_P4CBtOBwjTQC2OsBn2g3tDzKVnt4WF2kKyf6N2IAXYHem_TSDd-T2-8Q51_A71H-zAmeo07CHaixgd660MCR7-hPSqD3_Y-2kjzdJvtcEpxMbK_MNC1DWE8Aq_JCwMu4puln5Kvlxd36-ti8_nq0_p8U2jRcFVUILQxDWjeKyXavlFYo1BiUKatpCxlfuBYGhjAlC3vKzmUupF1DU0z1NiIU_Lh0XcX_M8ZY-q2Nmp0Dib0c-zylURVV1WdSflI6uBjDGi6XbBbCIeOs-4YQ5dj6P6PIcveLQvmfovDk2i5ewbeLwBEDc4EmLSN_7iybCWTtXzav_cuYYg_3LzH0I0ILo0dyyUbUee8OWMqTwX7G_If1CSirQ</recordid><startdate>201007</startdate><enddate>201007</enddate><creator>Amitrano, Lucio</creator><creator>Guardascione, Maria Anna</creator><creator>Menchise, Antonella</creator><creator>Martino, Rossana</creator><creator>Scaglione, Mariano</creator><creator>Giovine, Sabrina</creator><creator>Romano, Luigia</creator><creator>Balzano, Antonio</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201007</creationdate><title>Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver Cirrhosis</title><author>Amitrano, Lucio ; Guardascione, Maria Anna ; Menchise, Antonella ; Martino, Rossana ; Scaglione, Mariano ; Giovine, Sabrina ; Romano, Luigia ; Balzano, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3817-5a3cff8ac1b7739b87e6e373d7f95442487e1e2fadaf291b54d2c8466a88d6e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Cardiology. Vascular system</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Heparin, Low-Molecular-Weight - administration & dosage</topic><topic>Heparin, Low-Molecular-Weight - adverse effects</topic><topic>Heparin, Low-Molecular-Weight - therapeutic use</topic><topic>Humans</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Other diseases. Semiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Portal Vein</topic><topic>Treatment Outcome</topic><topic>Venous Thrombosis - drug therapy</topic><topic>Venous Thrombosis - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Amitrano, Lucio</creatorcontrib><creatorcontrib>Guardascione, Maria Anna</creatorcontrib><creatorcontrib>Menchise, Antonella</creatorcontrib><creatorcontrib>Martino, Rossana</creatorcontrib><creatorcontrib>Scaglione, Mariano</creatorcontrib><creatorcontrib>Giovine, Sabrina</creatorcontrib><creatorcontrib>Romano, Luigia</creatorcontrib><creatorcontrib>Balzano, Antonio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Amitrano, Lucio</au><au>Guardascione, Maria Anna</au><au>Menchise, Antonella</au><au>Martino, Rossana</au><au>Scaglione, Mariano</au><au>Giovine, Sabrina</au><au>Romano, Luigia</au><au>Balzano, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver Cirrhosis</atitle><jtitle>Journal of clinical gastroenterology</jtitle><addtitle>J Clin Gastroenterol</addtitle><date>2010-07</date><risdate>2010</risdate><volume>44</volume><issue>6</issue><spage>448</spage><epage>451</epage><pages>448-451</pages><issn>0192-0790</issn><eissn>1539-2031</eissn><coden>JCGADC</coden><abstract>BACKGROUNDTreatment of portal vein thrombosis (PVT) in patients with liver cirrhosis is not well established.
AIMWe intended to assess the safety and efficacy of low molecular weight heparin (LMWH) to treat PVT in cirrhotic patients.
STUDYAll 39 patients diagnosed with non-neoplastic PVT and cirrhosis from June 2005 to December 2006 were evaluated for anticoagulation therapy (AT). PVT was occludent in 15.4%, partial in 64.1%, and portal cavernoma presented in 20.5%. Twenty-eight patients received 200 U/kg/d of enoxaparin for at least 6 months. In 39.3% of patients PVT was an occasional finding, in 10.7% presented with acute abdominal pain, in 50% with bleeding from gastroesophageal varices. In this last group LMWH was started after endoscopic eradication of varices by band ligation.
RESULTSComplete recanalization of portal vein occurred in 33.3%, partial recanalization in 50% and no response in 16.7% of patients. Further 12 patients who continued AT obtained complete recanalization at a median time of 11 months (range 7 to 17 mo). Overall, a complete response was obtained in 75% of patients. No significant side effects, particularly bleeding complications, were observed during the treatment.
CONCLUSIONSLMWH demonstrated safe and effective in the treatment of PVT in patients with liver cirrhosis.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>19730112</pmid><doi>10.1097/MCG.0b013e3181b3ab44</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0192-0790 |
| ispartof | Journal of clinical gastroenterology, 2010-07, Vol.44 (6), p.448-451 |
| issn | 0192-0790 1539-2031 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733356556 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Aged Anticoagulants - administration & dosage Anticoagulants - adverse effects Anticoagulants - therapeutic use Biological and medical sciences Blood and lymphatic vessels Blood. Blood coagulation. Reticuloendothelial system Cardiology. Vascular system Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Female Gastroenterology. Liver. Pancreas. Abdomen Heparin, Low-Molecular-Weight - administration & dosage Heparin, Low-Molecular-Weight - adverse effects Heparin, Low-Molecular-Weight - therapeutic use Humans Liver Cirrhosis - complications Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Other diseases. Semiology Pharmacology. Drug treatments Portal Vein Treatment Outcome Venous Thrombosis - drug therapy Venous Thrombosis - etiology |
| title | Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver Cirrhosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A16%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Efficacy%20of%20Anticoagulation%20Therapy%20With%20Low%20Molecular%20Weight%20Heparin%20for%20Portal%20Vein%20Thrombosis%20in%20Patients%20With%20Liver%20Cirrhosis&rft.jtitle=Journal%20of%20clinical%20gastroenterology&rft.au=Amitrano,%20Lucio&rft.date=2010-07&rft.volume=44&rft.issue=6&rft.spage=448&rft.epage=451&rft.pages=448-451&rft.issn=0192-0790&rft.eissn=1539-2031&rft.coden=JCGADC&rft_id=info:doi/10.1097/MCG.0b013e3181b3ab44&rft_dat=%3Cproquest_cross%3E733356556%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733356556&rft_id=info:pmid/19730112&rfr_iscdi=true |